scholarly journals Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil treatment in Brazilian female pattern hair loss patients

2019 ◽  
Vol 33 (1) ◽  
Author(s):  
Paulo Müller Ramos ◽  
Rodney Sinclair ◽  
Hélio Amante Miot ◽  
Andy Goren
Keyword(s):  
Hair Loss ◽  
Hair Follicles ◽  
Female Pattern Hair Loss ◽  
Topical Minoxidil

scholarly journals Diagnosis and Management of Female Pattern Hair Loss

2020 ◽  
Vol 4 (1) ◽  
pp. 29-47
Author(s):  
Sarah Diba ◽  
Maria Mayfinna Gozali ◽  
Yuli Kurniawati
Keyword(s):  
Hair Loss ◽  
Clinical Manifestations ◽  
Term Treatment ◽  
Hair Follicles ◽  
Low Level Laser Therapy ◽  
Female Pattern Hair Loss ◽  
Level Laser ◽  
Long Term Treatment ◽  
Topical Minoxidil

Abstract Female pattern hair loss (FPHL) is the most common hair loss in post-puberty female. Prevalence of this nonscarring alopecia increases with age.  The etiology of FPHL is still unclear, but hormonal and genetic factors are associated with pathogenesis of FPHL. Hormonal factor in FPHL is not as strong as in male pattern hair loss (MPHL). Clinical manifestations of FPHL are characterized by nonscarring baldness with shortening anagen phases and miniaturization of hair follicles, predominantly occur at the vertex, middle, and frontal regions. Hair shedding occurs progressively. The diagnosis of FPHL is established based on clinically. Classification of FPHL is according to Ludwig's criteria. Current FDA-approved FPHL therapy is topical minoxidil 2%, hair transplantation, and low level laser therapy (LLLT). Anti-androgen therapy still needs to be investigated further. The prognosis of FPHL is poor because the progressiveness continues with age. Long term treatment required for FPHL because it is a chronic residif disease. The treatment only prevents the progression of hair loss and does not cure. 

scholarly journals A randomised trial of 5% minoxidil versus combination of 5% minoxidil and oral spironolactone in treatment of female pattern hair loss

2019 ◽  
Vol 5 (4) ◽  
pp. 668
Author(s):  
Nachiket Madhukarrao Palaskar ◽  
Nitin Dinkar Chaudhari ◽  
Garima Laxminarayan Balpande ◽  
Swapna Subhash Khatu
Keyword(s):  
Combination Therapy ◽  
Hair Loss ◽  
Tertiary Care ◽  
Randomised Trial ◽  
Life Questionnaire ◽  
Care Hospital ◽  
Female Pattern Hair Loss ◽  
Group I ◽  
Topical Minoxidil ◽  
Group Ii

<p class="abstract"><strong>Background:</strong> Female pattern hair loss (FPHL) is a common form of nonscarring hair loss. We compared the usefulness and safety of topical minoxidil alone with combination of oral spironolactone and topical minoxidil in the treatment of FPHL.</p><p class="abstract"><strong>Methods:</strong> This prospective, single-centre, randomised open label study over 100 patients attending tertiary care hospital in Mumbai during period December 2011 to June 2012. The data were entered into SPSS version 21 for analysis. Data collected were coded and described as frequency and percentage for qualitative data and means and standard deviation for quantitative data. Statistical analysis was done using chi-square and student t test. Statistical significance was considered if p value was less than 0.05.<strong></strong></p><p class="abstract"><strong>Results:</strong> There were 48 patients in Group I and 46 patients in Group II. At 6 months, significantly higher mean Sinclair grade was observed among Group I patients as compared to Group II patients (2.85±0.68 vs 2.56±0.50, p=0.02). We observed a significant improvement in women’s androgenetic alopecia quality of life questionnaire in Group I patients at 12 months after treatment (26.93±2.25 vs 23.47±2.95, p&lt;0.001). Minoxidil and spironolactone were tolerated well by the patients.</p><p class="abstract"><strong>Conclusions:</strong> Combination therapy of topical minoxidil and oral spironolactone has an additive effect. However, plateau of effectiveness of the combination therapy in normoandrogenic patients at 6 months of therapy was observed. We recommend the combination for 6 months and continuation of therapy with minoxidil only.</p>

scholarly journals Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin® with Marilex® in Pattern Hair Loss and Telogen Effluvium

2020 ◽  
Vol 2020 ◽  
pp. 1-17
Author(s):  
Jan Wadstein ◽  
Erling Thom ◽  
Aida Gadzhigoroeva
Keyword(s):  
Replacement Therapy ◽  
Hair Loss ◽  
Hair Growth ◽  
Relative Concentration ◽  
Follicular Phase ◽  
Hair Follicles ◽  
Growth Disorders ◽  
Female Pattern Hair Loss ◽  
Functional Involvement ◽  
Pathogenetic Factor

Follicular proteoglycans are key players with structural, functional, and regulatory roles in the growth and cycling behaviour of the hair follicles. The expression pattern of specific proteoglycans is strongly correlated with follicular phase transitions, which further affirms their functional involvement. Research shows that bioactive proteoglycans, e.g., versican and decorin, can actively trigger follicular phase shift by their anagen-inducing, anagen-maintaining, and immunoregulatory properties. This emerging insight has led to the recognition of “dysregulated proteoglycan metabolism” as a plausible causal or mediating pathology in hair growth disorders in both men and women. In support of this, declined expression of proteoglycans has been reported in cases of anagen shortening and follicular miniaturisation. To facilitate scientific communication, we propose designating this pathology “follicular hypoglycania (FHG),” which results from an impaired ability of follicular cells to replenish and maintain a minimum relative concentration of key proteoglycans during anagen. Lasting FHG may advance to structural decay, called proteoglycan follicular atrophy (PFA). This process is suggested to be an integral pathogenetic factor in pattern hair loss (PHL) and telogen effluvium (TE). To address FHG and PFA, a proteoglycan replacement therapy (PRT) program using oral administration of a marine-derived extract (Nourkrin® with Marilex®, produced by Pharma Medico Aps, Aarhus, Denmark) containing specific proteoglycans has been developed. In clinical studies, this treatment significantly reduced hair fall, promoted hair growth, and improved quality of life in patients with male- and female-pattern hair loss. Accordingly, PRT (using Nourkrin® with Marilex®) can be recommended as an add-on treatment or monotherapy in patients with PHL and TE.

scholarly journals Investigating the Safety and Efficacy of Platelet-Rich Plasma (PRP) Treatment for Female Androgenetic Alopecia: Review of the Literature

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 311
Author(s):  
Santo Raffaele Mercuri ◽  
Giovanni Paolino ◽  
Matteo Riccardo Di Nicola ◽  
Laura Vollono
Keyword(s):  
Hair Loss ◽  
Platelet Rich Plasma ◽  
Androgenetic Alopecia ◽  
Cochrane Central Register ◽  
Review Of The Literature ◽  
Psychosocial Burden ◽  
Female Pattern Hair Loss ◽  
Central Register ◽  
Topical Minoxidil

Background: female androgenetic alopecia (FAGA) is a common cause of non-scarring alopecia in women, affecting approximately 40% of women by age 50, bearing a significant psychosocial burden on affected patients. Platelet-rich plasma (PRP) has been widely investigated as a potential effective treatment for several dermatological conditions, including male androgenetic alopecia (MAGA). However, few studies have been conducted focusing on the use of PRP in FAGA. The aim of this review was to identify reports that investigated the use of PRP for the treatment of FAGA. Methods: Electronic databases of MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to September 2020 have been searched using different combinations of the following terms: “androgenetic alopecia,” “FAGA,” “female pattern hair loss,” “platelet-rich fibrin,” “platelet-rich plasma,” and “PRP”. Results and conclusions: Eight (n = 8) clinical studies consistent with our research were identified. A total of 197 subjects has been enrolled in the included studies. All of them were adult female patients (mean age: 38.9) affected by female pattern hair loss. PRP is a well-tolerated procedure which showed promising results in males-only and mixed populations of AGA patients. PRP showed to produce high levels of satisfaction and improvement in the quality of life in patients affected by FAGA. In the light of this evidence, PRP may be proposed in patients who did not respond or did not tolerate topical minoxidil, as well as in combination with topical and oral treatments.

scholarly journals Pharmacological therapeutics in androgenetic alopecia

2020 ◽  
Vol 63 (5) ◽  
pp. 277-285
Author(s):  
Doyoung Kim ◽  
Sujin Park
Keyword(s):  
Hair Loss ◽  
Treatment Options ◽  
Daily Intake ◽  
Androgenetic Alopecia ◽  
Men And Women ◽  
Reductase Inhibitors ◽  
Female Pattern Hair Loss ◽  
Evidence Quality ◽  
Topical Minoxidil ◽  
Current Guidelines

Androgenetic alopecia (AGA) is the most common type of hair loss and affects both men and women. Male pattern hair loss shows characteristic frontal recession and vertex baldness, whereas female pattern hair loss produces diffuse alopecia over the mid-frontal scalp. AGA is mediated by increased androgen susceptibility in affected scalp hairs. 5α-Reductase converts testosterone into dihydrotestosterone, a potent androgen, in the scalp. Both androgen receptors and 5α-reductase have higher expression levels in the balding scalp than in non-affected regions. Increased androgen susceptibility induces hair follicle miniaturization, which leads to the progressive loss of thicker terminal hairs in the balding scalp. Currently, topical minoxidil and oral 5α-reductase inhibitors, such as finasteride and dutasteride, are approved options for the pharmacological treatment of AGA. Topical minoxidil remains the mainstay of therapy for mild to moderate AGA in both men and women. The daily intake of 1-mg finasteride or 0.5-mg dutasteride shows better efficacy than topical minoxidil in regard to hair regrowth in male AGA. Anti-androgens can be used in female AGA wit clinical and biochemical evidence of hyperandrogenism. Patients may be overwhelmed and confused by the variety of treatment options for AGA management, including over-the-count drugs with low evidence quality. Therefore, physicians must be aware of the current guidelines for the management of AGA based on evidence-based approaches to select better options for patients.

scholarly journals Managing patterned hair loss – a hair raising task!

2021 ◽  
Vol 1 ◽  
pp. 55
Author(s):  
Aseem Sharma ◽  
Manasi Shirolikar ◽  
Madhulika Mhatre
Keyword(s):  
Hair Loss ◽  
Clinical Presentation ◽  
Short Review ◽  
Population Based ◽  
Androgenetic Alopecia ◽  
Psychosocial Burden ◽  
Weighted Averages ◽  
Female Pattern Hair Loss ◽  
Topical Minoxidil

Diffuse alopecia wields a significant psychosocial burden by virtue of its clinical presentation and visibility. Patterned alopecia is an umbrella term with the focus point being androgen-mediated alopecias - androgenetic alopecia/male pattern baldness/male androgenetic alopecia and female pattern hair loss/female androgenetic alopecia, both of which have a genetic susceptibility that alters the follicular sensitivity to circulating androgens. Diffuse alopecia affects nearly half the population based on weighted averages. It may present with hair shedding and hair thinning (miniaturization) or a combination. With the female variant, the role of androgens is not fully delineated; hence, the term female pattern hair loss which has replaced prior nomenclature. Managing patterned hair loss has seen a sea change in the last decade, moving well beyond the FDA-approved modalities - topical minoxidil and oral finasteride. Through this short review, the authors have attempted to condense existing information into a ready reference.

Sign in / Sign up

Export Citation Format

Share Document